Loading
A phase 1/2 trial of Garsorasib, Cetuximab and Pembrolizumab in non-small-cell lung cancer, run by InventisBio Co., Ltd, active and no longer recruiting.
Study to Evaluate D-1553 in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT04585035 by InventisBio Co., Ltd, with 180 participants enrolled, started 2020-10-02 and due to reach its primary completion in 2024-04-30. Interventions recorded: D-1553 and D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares InventisBio, Garsorasib, KRAS & RAS inhibitors, Small-molecule kinase inhibitors and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Shares Garsorasib, KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Cetuximab, Merck & Co. (MSD) and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/